Novartis: Decentralized trials could expand enterprise around the world

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/RomoloTavani)
(Image: Getty/RomoloTavani)
Novartis hopes to eventually recruit ‘a significant portion’ of patients into a decentralized clinical trial model that has the potential to increase the company’s reach globally, says exec.

Last week Novartis and Science 37 announced​ an expanded alliance through which the companies will launch up to 10 “decentralized” clinical trials across the US.

Decentralized trials shift some or all aspects of a clinical trial from a central site, such as a hospital, to the participant’s home or physician’s office.

“By bringing the trial to the patient, Novartis aims to decrease the burden of clinical trial participation on patients and trial centers,”​ Jake LaPorte, global head of digital development at Novartis told

The more flexible approach also could benefit underrepresented populations.

LaPorte said: “This approach also has the potential to increase the reach of our leading drug development and clinical trials enterprise into under-represented and underserved populations around the world, improving the caliber and quantity of data available to aid in drug discovery and development.”

Currently, Novartis is in the process of selecting specific indication and trials where it will deploy the decentralized approach, which leverages Science 37’s technology to enable patient participation using mobile devices and telemedicine services.

LaPorte said the characteristics of the target patient population, including size, will be defined after these decisions have been made.

The studies will use both decentralized and traditional models, “with the aspiration of attaining increasing degrees of decentralization towards a mostly ‘site-less’ model overtime,”​ he added.

Our aspiration, overtime, is to recruit a significant portion of patients into this decentralized model when deployed on a clinical trial.”

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers